Simone FishburnUnclaimed
Host of The BioCentury Show.
1 Feed-stated
Counts Verified and Feed-stated credits: what a show's own feed states, or a confirmation backs. See the record
- Host
Claim this profile Add a creditIs this you? Claiming needs a free account. You sign in or join, then come straight back here.
This profile is unclaimed. PodSubs built it from public show feeds and credits. The person it is about has not reviewed it yet.
PodCred record
PodCred is the verified record of where Simone has worked and appeared. These credits come from the shows' own feeds and wait for people who were there to confirm them.
Worked with Simone on a show? This is where you give them credit.
Shows they work on now
1 show
Is an appearance missing?
People get invited back because someone remembered they were great. If you heard this person on a show and it is not listed here, add it. Your memory might be the reason they get their next invitation.
No account needed. Anyone can give a credit.
Experience, education, skills, and recommendations start empty. They fill in when Simone claims this profile.
Recommendations
No recommendations for Simone yet.
Recommendations open once Simone claims the profile.
Posts
No posts yet. Posts Simone shares on PodSubs, and what Simone publishes on Substack, YouTube and elsewhere, will show here.
Recent episodes
From the shows they work on now
Ep. 124 - Texas Medical Center’s William McKeon on making Texas the U.S. pilot for faster trials
Texas Medical Center CEO William McKeon wants Texas to serve as the U.S. pilot for faster, cheaper clinical trials. In an interview with BioCentury Editor in Chief Simone Fishburn on The BioCentury Show, McKeon...
Ep. 123 - Gilde’s Joep Muijrers on why patients belong in the investment process
On this edition of The BioCentury Show, Gilde's Joep Muijrers joins BioCentury’s Stephen Hansen to discuss how the firm’s Impact Council of former regulators, payers, HTA leaders, and patient advocates shapes its...
Ep. 122 - Tigermed's Britney Winterberger's take on running trials in the U.S. and China
Tigermed, the largest clinical CRO in China, has expanded into more than 50 countries and is growing its North American operations, offering full-service support from preclinical through Phase IV. On this sponsored...
Ep. 121 - Arrowhead’s Chris Anzalone on the future of RNAi
Arrowhead Pharmaceuticals can now deliver siRNA to seven cell types, and new data showing subcutaneous delivery to the brain could push RNAi therapies well beyond the liver. On this edition of The BioCentury Show,...
Ep. 120 - Canaan’s Julie Grant on building biotechs in white spaces
Untapped multibillion-dollar markets are hiding in plain sight where patients endure mediocre generic standards of care, according to Canaan General Partner Julie Grant, co-founder and first CEO of Day One, which...
Ep. 119 - Blackstone's Galakatos on funding biotech's hardest mile
On this edition of The BioCentury Show, Nick Galakatos, Global Head of Life Sciences at Blackstone, joins Editor in Chief Simone Fishburn to discuss the path from Clarus to Blackstone's new $6.3 billion fund, and the...
Ep. 118 - Regeneron's Gonçalo Abecasis on turning genetic data into drug targets
On This Edition of The BioCentury Show, Gonçalo Abecasis, SVP and Chief Genomics and Data Sciences Officer at the Regeneron Genetics Center, joins BioCentury’s Tierney Baum to discuss genetics as a scalable drug...
Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient
The Critical Path Institute’s One to Millions Initiative is using individualized rare disease therapies as the starting point for a development framework that could eventually extend across all genetically defined...
Ep. 116 - Ovid's Jeremy Levin on biotech in the balance
Throughout his career, which has included serving as president and CEO of Teva, chair of BIO, and a leader or senior executive of large and small biopharma companies, Jeremy Levin has challenged the industry to live up...
Ep. 115 - Initiate's Owens on what it takes to be AI-native
As AI becomes increasingly commoditized, Initiate Ventures' Jessica Owens argues healthcare and life sciences companies need to use it to solve historically intractable problems, not just streamline workflows. On The...
